Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$820M |
| 2 |
Microsoft
MSFT
|
+$811M |
| 3 |
McDonald's
MCD
|
+$804M |
| 4 |
Coca-Cola
KO
|
+$655M |
| 5 |
Amazon
AMZN
|
+$646M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$1.64B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.1B |
| 3 |
Strategy Inc
MSTR
|
+$564M |
| 4 |
Kroger
KR
|
+$558M |
| 5 |
Danaher
DHR
|
+$494M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 3.33% |
| 2 | Healthcare | 3.23% |
| 3 | Consumer Discretionary | 2.55% |
| 4 | Financials | 2.55% |
| 5 | Industrials | 1.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAPS
12101
CALL
DELISTED
WM TECHNOLOGY INC A
MAPS
| $16.5K | ﹤0.01% |
18,400
| – | – |
|
12102
Calidi Biotherapeutics
CLDI
$3.89M
| $16.4K | ﹤0.01% |
+371
| New | +$28.8K |
|
12103
CALL
Q32 Bio
QTTB
$451M
| $16.2K | ﹤0.01% |
+10,900
| New | +$18.6K |
|
12104
CALL
Fossil Group
FOSL
$329M
| $16.1K | ﹤0.01% |
10,900
-36,100
| -77% | -$45.5K |
|
|
UBX
12105
CALL
DELISTED
Unity Biotechnology
UBX
| $16.1K | ﹤0.01% |
42,300
+3,400
| +9% | +$2.91K |
|
12106
PUT
SmartRent
SMRT
$286M
| $16K | ﹤0.01% |
16,200
+16,000
| +8,000% | +$14.3K |
|
12107
E-Power Inc
EPOW
$20.6M
| $15.8K | ﹤0.01% |
17,314
-16,258
| -48% | -$15.4K |
|
12108
Onfolio Holdings
ONFO
$365K
| $15.8K | ﹤0.01% |
319
+50
| +19% | +$2.52K |
|
12109
PUT
Protalix BioTherapeutics
PLX
$179M
| $15.7K | ﹤0.01% |
10,600
-33,200
| -76% | -$67.9K |
|
12110
Theriva Biologics
TOVX
$10.5M
| $15.6K | ﹤0.01% |
+36,018
| New | +$29.2K |
|
12111
PUT
Grove Collaborative
GROV
$44M
| $15.4K | ﹤0.01% |
13,400
+2,600
| +24% | +$3.07K |
|
|
LSB
12112
DELISTED
LakeShore Biopharma
LSB
| $15.3K | ﹤0.01% |
14,963
+4,377
| +41% | +$5.5K |
|
|
AURE
12113
Aurelion Inc
AURE
$65.1M
| $15.1K | ﹤0.01% |
4,265
+1,808
| +74% | +$7.03K |
|
12114
BT Brands
BTBD
$7.85M
| $15.1K | ﹤0.01% |
+11,148
| New | +$13.5K |
|
12115
PUT
Fate Therapeutics
FATE
$308M
| $15K | ﹤0.01% |
13,400
+8,000
| +148% | +$9.3K |
|
|
SPHL
12116
Springview Holdings
SPHL
$6.15M
| $14.9K | ﹤0.01% |
+3,486
| New | +$14.3K |
|
|
PRHI
12117
Presurance Holdings
PRHI
$23.6M
| $14.9K | ﹤0.01% |
2,724
-1,909
| -41% | -$9.59K |
|
|
BRNS
12118
Barinthus Biotherapeutics
BRNS
$24.1M
| $14.8K | ﹤0.01% |
16,227
-9,945
| -38% | -$8.69K |
|
12119
Tenaya Therapeutics
TNYA
$163M
| $14.7K | ﹤0.01% |
+24,062
| New | +$12.2K |
|
12120
PEDEVCO
PED
$166M
| $14.6K | ﹤0.01% |
1,116
-3,598
| -76% | -$44.1K |
|
|
ASRT
12121
PUT
DELISTED
Assertio
ASRT
| $14.4K | ﹤0.01% |
1,500
-640
| -30% | -$6.15K |
|
12122
EpicQuest Education Group
EEIQ
$3.8M
| $14.3K | ﹤0.01% |
1,591
-2,544
| -62% | -$25.5K |
|
12123
Sadot Group
SDOT
$12.3M
| $14.2K | ﹤0.01% |
+54
| New | +$16.9K |
|
12124
CALL
Accuray
ARAY
$33.2M
| $14.1K | ﹤0.01% |
10,300
-4,300
| -29% | -$6.37K |
|
|
THM
12125
International Tower Hill Mines
THM
$712M
| $14K | ﹤0.01% |
16,385
-184,403
| -92% | -$140K |
|
Similar funds
Ken Griffin's Q2 2025 Portfolio in Review
As of Q2 2025, Ken Griffin held 15,819 positions worth $576B, up 9.2% from $527B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ken Griffin withdrew a net $29.1B in Q2 2025, closing 3,524 positions and reducing 5,141 holdings. Its most notable exit was Kroger, an estimated $558M position sold in full.
By sector, the portfolio is most concentrated in Technology at 3.3% of assets, up from 2.9% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Ken Griffin opened a new position in Walmart Inc worth $401M.
- Ken Griffin's largest Q2 2025 buy was Walmart Inc: 4,099,492 shares worth $401M.
- Ken Griffin added most to NVIDIA in Q2 2025, an estimated $820M increase.
- Ken Griffin's biggest Q2 2025 reduction was Charles Schwab, cutting an estimated $1.64B.
- Ken Griffin fully exited Kroger in Q2 2025, selling an estimated $558M.
- Ken Griffin's ten largest holdings make up 27% of its $576B portfolio in Q2 2025.
- Ken Griffin opened 1,459 new positions and closed 3,524 in Q2 2025.
- Ken Griffin's portfolio value rose 9.2% quarter-over-quarter to $576B.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.